By Christy Santhosh June 22 (Reuters) - Merck said on Monday its experimental drug met the main goal and key secondary goals ...

Merck & Co Inc. MRK on Monday said its investigational therapy tulisokibart achieved the primary endpoint in a Phase 3 study ...

Merck on Monday said the Phase 3 induction-only study met its primary endpoint of clinical remission at week 12, as well as key secondary endpoints in patients with moderately to severely active ...

While Wall Street fretted over the future of its biggest blockbuster, a pair of new drugs were already showing the company's ...

These positive Phase 3 induction results for tulisokibart are the first for an anti-TL1A biologic. They represent an important step forward for patients with moderately to severely active ulcerative ...

With pharma heavyweights clashing against one another and reeling in major sales in the ulcerative colitis (UC) | Merck is ...

Merck & Co.’s first-in-class HIF-2 alpha inhibitor Welireg is touching down in the clear cell renal cell carcinoma (ccRCC) | ...

In Q1, revenue of Merck's oncology unit rose 9.6% year-over-year to about $8.8 billion. And in my opinion, the key ...

Merck & Co., Inc. (NYSE:MRK) is included among the Billionaire Ken Fisher’s Top 11 Dividend Stock Picks. Reuters reported on ...

Merck & Co., Inc. (NYSE:MRK) is one of the 10 Undervalued Counter Cyclical Stocks to Buy Now. On June 12, 2026, Merck & Co., ...

Merck looks like a buy-the-dip at $114.90 with a 3% yield and 12x forward P/E. Click here to read more on the MRK stock.